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Wogonin  inhibited  C6  cells  growth
and  arrested  at G0/G1  phase  of the
cell cycle.
Wogonin  induced  typical  morpho-
logical  changes  and  an  increase  in
GFAP level.
Induction  of  cell  differentiation  by
wogonin  ascribed  to the  restrain  of
GSK-3/-catenin  pathway.
Blocking  GSK-3/-catenin  signaling
promotes  the  glial  differentiation  of
glioma  cells.
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a  b  s  t  r  a  c  t
Malignant  gliomas  are  the most  common  and  most  aggressive  primary  brain  tumor,  and for  which  dif-
ferentiation  therapy  has  emerged  as a promising  candidate  strategy.  In this  study,  we used  in  vitro  and
in  vivo assays  to  examine  the  differentiation  effects  of  wogonin,  a major  active  constituent  of Scutellaria
baicalensis,  on  glioma  C6 and  U251  cells.  We found  that wogonin  can  suppress  cell  proliferation  and  induce
G0/G1  arrest  under  a concentration-dependent  manner.  Wogonin  also  triggered  signiﬁcant  reduction  in
the G1  cell-cycle  regulatory  proteins  cyclin  D1,  cyclin-dependent  kinase  2  and  4  along  with  overexpress-
ion  of  cell-cycle  inhibitory  proteins  p27.  Immunoﬂuorescence  and  western  blot  analysis  indicated  that
wogonin  increased  the  expression  of lineage-speciﬁc  differentiation  marker  glial  ﬁbrillary  acidic  protein
(GFAP).  In mechanisms,  we  veriﬁed  that  wogonin  signiﬁcantly  diminished  the  phosphorylated  level  of
protein  kinase  B (AKT),  and maintenance  of low  -catenin  expression  level  was  dependent  on  glyco-
gen  synthase  kinase  3 (GSK3)  activation  at Ser9.  Blocking  GSK3/-catenin  pathway  was required
for  wogonin-induced  proliferation  inhibition  and  terminal  differentiation  by using  canonical  activator
lithium  chloride  (LiCl)  and inhibitor  dickkopf-1  (Dkk1).  Moreover,  intravenous  administration  of  wogonin
delayed  the growth  of C6 gliom
mechanistic  support  for wogo
more,  inhibition  of GSK3/-c
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. Introduction
Glioblastoma multiforme (GBM) is the most common primary
umor of the brain and one of the most lethal malignant tumors,
hose highly invasion and metastasis leave rare opportunity for
ure. In spite of advances in surgery, optimized radiotherapy and
hemotherapy, patients face a dismal prognosis and the median
urvival rates range from 12 to 15 months (Louis et al., 2007).
herefore, great efforts have been made to develop novel adjuvant
herapeutic strategies.
Differentiation therapy, an approach to the treatment of
dvanced or aggressive malignancies, involves using agents, alone
r in combination, that promote cancer cells maturation and dif-
erentiation into mature cells (Leszczyniecka et al., 2001). This
herapeutic protocol is based on the concept that cancer cells dis-
lay alterations in differentiation states and growth control that
an be corrected by appropriate differentiation inducers. More
nd more studies conﬁrm that this therapy is effective in the
reatment of several types of cancer cells. The ﬁrst differenti-
tion agent found to be successful was all-trans-retinoic acid
ATRA) in the treatment of acute promyelocytic leukemia (APL),
emonstrating the remarkable efﬁcient to induce glioma cells dif-
erentiation (Bianchi et al., 2008; Kiningham et al., 2008; Redova
t al., 2010; Siddikuzzaman Guruvayoorappan and Berlin Grace,
011; Zhang et al., 2008d). Subsequently, several differentiation-
nducing agents, including cholera toxin, capsaicin, valproic acid,
eomycin, HMBA, saikosaponins, were reported to be capable of
nhibiting cells growth and inducing glioma cells differentiation
Benitez et al., 2008; Cuevas et al., 2004; Gil and Kang, 2008;
hirsat et al., 2001; Tsai et al., 2002; Xu et al., 2009). In addition,
euroblastoma cells exhibited effective differentiation with eleva-
ion of intracellular adenosine 3′,5′-cyclic monophosphate (cAMP)
oncentration after treatment with cyclic nucleotide phosphodi-
sterase inhibitors or adenylate cyclase activators (Chang et al.,
011; Hai et al., 2009). Although the roles of differentiation inducers
btained growing concern, effective differentiation agents for the
reatment of malignant glioma have not yet been found (Kawamata
t al., 2006).
Wogonin, 5,7-dihydroxy-8-methoxyﬂavone, is a naturally
onoﬂavonoid extracted from Scutellaria baicalensi Georgi,  which
as been shown to have anti-inﬂammatory, anticancer, antivi-
al and neuroprotective effects. We  have previously reported
hat wogonin could suppress promyelocytic leukemia U-937 cells
rowth, inducing the granulocytic differentiation and G1 arrest of
-937 and NB4 cells by up-regulating the expression of PLSCR1
ene (Zhang et al., 2008a,b). However, the potential effect of wogo-
in on the induction of solid tumors differentiation has not yet been
xplored. In addition, a recent study has indicated that wogonin can
nduce differentiation of neural precursor cells into neuronal cells
oth in culture and in vivo (Lim et al., 2010). These data prompt us
o investigate the possible roles of wogonin on glioma cells differ-
ntiation.
In this study, we investigated the effects of wogonin on cell
urvival and differentiation in glioma C6 and U251 cells and
xplored the underlying molecular mechanisms, in order to ﬁnd
he potential therapeutic function of wogonin in the treatment
f glioblastoma. Using a syngeneic rat glioma tumor model, com-
rising orthotopic transplantation of C6 glioma cells into SD
ats, we reported delayed growth of tumor following intravenous
dministration of wogonin. And we also examined whether the
lioma C6 cells pretreated with wogonin prior to transplanta-
ion into the adult rat brain can be efﬁciently differentiated into
ature astrocytes cells. Our results demonstrated that wogonin
ffectively induced G0/G1 phase cell cycle arrest and the dif-
erentiation of glioma cells focusing on the GSK-3/-catenin
ignaling.rs 222 (2013) 212– 223 213
2. Materials and methods
2.1. Chemicals and antibodies
Wogonin (purity > 99%) was isolated from S. baicalensis Georgi according to
the  procedure reported previously (Hui et al., 2002). Stock solutions of wogo-
nin were dissolved in dimethyl sulfoxide (DMSO), stored at 20 ◦C and diluted
with medium until needed. The ﬁnal DMSO concentration in all drug-treated
cells was <0.1%. All-trans retinoic acid (ATRA, used as positive control), DAPI,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were all pur-
chased from Sigma–Aldrich (St. Louis, MO,  USA). Stock solutions of ATRA were
prepared in DMSO at 10 mM and stored at −20 ◦C wrapped with aluminum foil
to  avoid direct light irradiation. Dulbecco’s Modiﬁed Eagle Medium (DMEM),
penicillin–streptomycin and trypsin–EDTA were purchased from Life Technologies
Corporation (Grand Island, NY, USA). Sources of the antibodies are as follows: GFAP
(sc-33673), CDK2 (sc-163), CDK4 (sc260) and -actin (sc-1616) were from Santa
Cruz Biotechnology (Santa Cruz Biotechnology Inc., CA); Cyclin D1 (#2922), p27
Kip1 (#2552), Phospho-Akt (Ser473, #9271), Akt (#9272), -catenin (#9562) and
Phospho--catenin (Ser33/37/Thr41, #9561) were from Cell Signaling Technology
(Beverly, MA); GSK3 (BS1402) and p-GSK3 (S9, BS4084) were from Bioworld
Technology Inc. (St. Louis, MN,  USA). IRDyeTM 800 conjugated secondary antibodies
were obtained from Rockland Inc. (Bedford, PA).
2.2. Cell culture
Rat C6 and human U251 glioma cell lines were obtained from the American Type
Culture Collection (Manassas, VA, USA), and routinely cultured in DMEM containing
10% fetal bovine serum, 1% penicillin and streptomycin, maintained in a humidiﬁed
atmosphere of 95% air, 5% CO2 at 37 ◦C. Cells were plated in 6-well plates or plastic
incubating ﬂask and then treated with the various concentrations of wogonin and
ATRA.
2.3. Proliferation assay
C6 and U251 cells were seeded into 6-well plates at a density of 5 × 105 per
well and were treated as indicated. Cells were collected after trypsin digestion
and  counted with a cell counting chamber (Qiujing, Shanghai, China) and micro-
scope (YS100; Nikon, Ibaraki, Japan). For cell viability assay, cells were plated into
96-well plates at approximately 8000/well in 100 l medium. Various compounds
were added to the cells at indicated concentrations and durations. Cell viability was
measured using an MTT  assay following the manufacturer’s protocol.
2.4. Clonogenic assay
Cells were plated in 35-mm dishes at 5000 cells per well in DMEM culture
medium. Plates were further incubated in incubator for 14 days until colonies were
large enough to be visualized. Colonies were stained with 0.01% Crystal violet for
1  h and counted under inverted microscope. Experiments were done in triplicate.
2.5. Cell cycle analysis
Cells were starved in serum-free medium for 24 h to be synchronized, and after
treatment with wogonin, cells were harvested and resuspended with 70% ethanol
overnight at 4 ◦C. Cells were spun down and incubated with the DNA-binding dye
propidium iodide (PI) solution [0.1% sodium citrate (w/v), 0.1% TritonX-100 (v/v),
and  50 mg/L PI in deionized water] for 30 min at room temperature. Finally, cells
were analyzed by FACSCalibur ﬂow cytometry (Becton Dickinson, San Jose, CA).
2.6. Immunoﬂuorescent staining
Cells were ﬁxed with 4% paraformaldehyde–PBS for 30 min, washed, and
blocked with PBS containing 1% BSA for 1 h at 37 ◦C. The primary antibodies were
diluted at certain concentration according to instructions. After being incubated
with  primary antibody for 2 h at 37 ◦C, cells were treated with the secondary anti-
body at appropriate dilution in 1% BSA for 1 h at 37 ◦C. Nuclei were stained with DAPI
(1  g/ml). Immunoﬂuorescence photomicrographs were captured using ﬂuorescent
microscope (Olympus IX51, Olympus Corporation, Tokyo, Japan).
2.7. Western blot assay
Cells were collected, washed twice with PBS and lysed in extraction buffer
(50  mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM PMSF, 1 mM EDTA, 1% Triton X-100
and 0.1% SDS, 200 mM b-mercaptoethanol, 1 mM phenylmethylsulfonyl ﬂuoride and
1  g/ml aprotinin) for 30 min on ice. The lysates were centrifuged at 13,000 × g for
15 min, and protein concentration in the supernatants was quantiﬁed by BCA assay.
Proteins were separated by 10% SDS–polyacrylamide gel electrophoresis and elec-
troblotted onto nitrocellulose membranes by standard procedures. After blocking
with  1% BSA in PBS for 1 h at 37 ◦C, the membranes were incubated for 2 h with pri-
mary antibodies at 37 ◦C followed by IRDye 800 conjugated secondary antibody for
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 h at 37 ◦C. Immunoreactive protein bands were detected with an Odyssey Scanning
ystem (LI-COR Inc., Lincoln, NE).
.8. Real-time quantitative PCR
Total RNA were extracted from C6 and U251 cells using TRIzol® Reagent (Invi-
rogen, Carlsbad, CA) and then the quality of total RNA was  assessed by the ratio
f  A260/A280 using a BioPhotometer (Eppendorf, Hamburg, Germany). 1 g of
otal RNA was  reverse-transcribed using PrimeScript®RT Reagent Kit with gDNA
raser (Perfect Real Time). Quantitative real-time PCR (q-PCR) was conducted fol-
owing the protocol supplied by TaKaRa SYBR Green Master Mix  kit. All the PCR
its were purchased from TaKaRa Biotechnology Co., Ltd. (Dalian, China). The rel-
tive amount of target mRNA was determined using the comparative threshold
Ct)  method by normalizing target mRNA Ct values to those for GAPDH (Ct). The
rimer sequences are as follows: rat GFAP, forward: 5′-ACCTCGGCACCCTGAGGCAG-
′ , reverse: 5′-CCAGCGACTCAACCTTCCTC-3′ , and human GFAP, forward: 5′-CTGC-
GCTCGATCAACTCA-3′ , reverse: 5′-TCCAGCGACTCAATCTTCCTC-3′; rat GAPDH, for-
ard: 5′-GTTACCAGGGCTGCCTTCTC-3′ , reverse: 5′-GGGTTTCCCGTTGATGACC-3′ ,
nd human GAPDH, forward: 5′-TGGGTGTGAACCATGAGAAG-3′ , reverse: 5′-
CTAAGCAGTTGGTGGTGC-3′ .
.9. Rat intracranial glioma models
To investigate whether wogonin facilitates the differentiation of C6 cells in vivo
s  well as in cultured cells, C6 cells treated with 25 M wogonin, 10 M ATRA or
ot  for 7 days were transplanted into the adult rat brain. For identiﬁcation within
he host tissue, C6 cells were labeled with a ﬂuorescence dye, DiI-C18-(3), followed
y  exposure to wogonin for 2 h prior to transplantation. Before transplantation, C6
ells were pretreated, and then collected, suspended in phosphate buffered saline,
omplemented with 2% of glutamine and 1% of penicillin streptomycin.
Sprague-Dawley rats weighing from 150 to 180 g were group-housed in a
emperature-controlled room with a 12 h:12 h light–dark cycle. Animal treatment
nd maintenance were carried out following the directions in the ethics approval
rom the Experimentation Ethics Review Committee of China Pharmaceutical Uni-
ersity.
Rats (n = 24) were accommodated for one week before experiment and then
ere randomly divided into three groups (control, wogonin and ATRA) with
ntracranial injection of different treatment conditions cells. After anesthetized with
quithensin (2 mL/kg i.p.), animals were placed in the stereotaxic device. A scalp inci-
ion was  made along the midline and a high-speed drill was  used to create a 0.5 mm
iameter burr hole in the skull. For each rat, a 10 l cell suspension (1 × 106 C6 cells)
as  injected over 10 min  at a depth of 6.0 mm into the right striatum (3.0 mm lat-
ral  to midline, 0.5 mm posterior to bregma) using automatic microinjector. 5 min
fter the injection, the needle was slowly removed, and the burr hole was  ﬁlled with
one wax. The wound was sutured together, and the rats were allowed to recover.
ll  rats were examined each day. Dead animals were studied, their brains removed
nd  kept in frozen pipes at −80 ◦C. After 20 days, the remaining animals were killed.
he brains were sectioned and prepared for histology and immunohistochemistry.
Then, for study the anti-glioma activity of wogonin in vivo, C6 cells were stereo-
actically injected into the right striatum of rats following the above method. Three
ays after tumor transplantation, animals were randomly divided into ﬁve groups:
aline control group, cisplatin (DDP) positive control group, 30 mg/kg wogonin
roup, 60 mg/kg wogonin group and 120 mg/kg wogonin group. After injecting C6
ells for 3 days, rats were treated by i.v. with saline, 5 mg/kg DDP, 30 mg/kg, 60 mg/kg
nd  120 mg/kg wogonin, respectively, every other day and continued for 20 days.
umor volume was  estimated following gadolinium enhanced T1-weighted MRI  (GE
edical Systems) on day 8, 13 and 18. Number of voxels in each slice (slice thickness
 mm,  total 18 slices) were counted using Image J software. Volume = Total number
f voxels × 0.015625 mm3. The brains were excised and then ﬁxed in 4% PFA–PBS
or  immunoﬂuorescence.
.10. General morphology and immunohistochemistry
Brain sections were cut using a cryostat (Leica CM 3050S) at 15 m and collected
n  glass slides coated with silane and poly-l-lysine. The sections were ﬁxed in 4%
araformaldehyde solution and then stored at −80 ◦C before processing. Microscopic
orphology of the brain was  assessed by hematoxylin–eosin staining of cryostat
ections. The tumor cross sectional areas were measured based on H&E stained
ryostat sections from perfusion-ﬁxed brains using computer-assisted image analy-
is as previously described. Tumor sizes were determined according to the following
ormula: tumor volume = (square root of maximum cross sectional area)3.
For  immunoﬂuorescence, brain cryostat sections were processed for indirect
mmunoﬂuorescence. Blocking was performed by incubating 60 min  at room tem-
erature with PBS containing 5% bovine serum albumin (PBS–BSA). Then, sections
ere incubated with primary antibodies overnight at 4 ◦C, with 3% BSA and 0.1%
riton-X. Slides were washed three times in PBS and exposed to FITC-conjugated
econdary antibodies for 2 h at room temperature. Nuclei were counterstained
ith DAPI. The immunoreactivity was ﬁnally examined under an Olympus confocal
icroscope.rs 222 (2013) 212– 223
The PCNA staining was  performed using a PCNA cell proliferation detection kit
(Keygen, Nanjing, China) according to the manufacturing instructions. Following
above-mentioned procedures, the frozen sections were blocked with 3% hydrogen
peroxide and 10% methanol for 20 min  with subsequent rinses with PBS. The spec-
imens were incubated with primary antibodies and second antibodies, subsequent
treated with the appropriate ABC-complex as chromogenic agent, resulting in brown
staining of antigen-expressing cells.
2.11. Statistical analysis
Data were analyzed using post hoc tests included the Student’s t-test and the
Tukey multiple comparison tests. All experiments reported here represent at least
triplicate independent replications. All data are represented as mean value ± SD and
the signiﬁcant difference is indicated as *P < 0.05, **P < 0.01.
3. Results
3.1. Wogonin’s effect on the cell viability of glioma C6 and U251
cells
To investigate the cytotoxicity of wogonin on glioma C6 and
U251 cells, we  examined cell viability using MTT  assay for 24 h. As
shown in Fig. 1A and B, wogonin inhibited the growth of C6 and
U251 cells in a concentration-dependent manner. We additionally
performed cell count assay showing that the effects of low con-
centration of wogonin (25 M,  50 M)  on cell growth over longer
period of time showed signiﬁcant proliferation inhibition (Fig. 1C
and D). Approximately 50% growth inhibition was observed when
C6 and U251 cells were exposed to 50 M wogonin for 72 h. This
is comparable to the results observed with 10 M ATRA, a known
differentiation agent for glioma cells. Next, wogonin-induced cell
reproductive death was also examined by evaluating the colony-
formation ability using clonogenic assay. As data shown in Fig. 1E
and F, the clone numbers of C6 and U251 cells treated with 50 M
wogonin were 62% and 57%, respectively, as much as that in control.
Obviously, treatment with wogonin showed signiﬁcant decrease in
cell survival in a dose-dependent manner.
3.2. Wogonin induces glioma cells at G1/G0 phase arrest
We  carried out FACS analysis on C6 and U251 cells treated with
various wogonin. As shown in Fig. 2A and B, wogonin treatment
(12.5, 25, 50 M)  for 24 h obviously depleted the G2/M population
in a dose-dependent manner. To further investigate whether cells
re-enter the cell cycle after wogonin treatment was removed for
4, 8, 12, and 24 h, we  respectively examined the sub-G1 groups of
C6 and U251 cells at each time point, which were pretreated with
50 M wogonin for 24 h. As shown in Fig. 2D, after wogonin was
removed for 24 h, cells began to re-enter new cell cycle, indicating
that the effect of wogonin inducing sub-G1 arrest was  reversible.
Next, we analyzed expression levels of principal cell-cycle regu-
latory proteins including cyclin D1, cyclin-dependent kinase 2, 4
and the cyclin-dependent kinase inhibitors p27. When cells were
treated with various concentrations (0–50 M)  of wogonin for 24 h,
the proteins levels of cyclin D1, CDK4, and CDK2 all decreased as the
wogonin concentration was  raised. In contrast, the 50 M wogo-
nin treatment resulted in an obvious increase in p27 protein levels
(Fig. 2E and F). These data indicate that wogonin induces G1/G0
phases arrest on glioma cancer cells.
3.3. Wogonin promotes the glial differentiation of glioma cells
Wogonin induced a dramatic change in glioma C6 cell morphol-
ogy. As shown in Fig. 3A, many smaller and spindle-shaped cells
with long synaptic-like structure formed after treatment of wogo-
nin (25 and 50 M).  Immunoﬂuorescence indicated that a dramatic
increase in GFAP production in C6 and U251 cells treated with
wogonin (25 M)  were remarkably similar to those treated with
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Fig. 1. Wogonin inhibits cell growth in glioma cells. Wogonin-induced cell deaths of two different glioma cells are shown in C6 (A) and U251 (B). Cells were treated within
0–200  M wogonin for 24 h and cell viability was  examined by MTT  assay. (C and D) The effect of wogonin on the growth of glioma cells compared with all-trans retinoic
a ATRA 
o pared
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(
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ocid  (ATRA). Cells were treated with different concentrations of wogonin or 10 M 
f  glioma cells. Data are presented as means ± SD (n = 3). Statistical differences com
TRA (10 M),  that is known to induce glioma cell differentiation
Fig. 3B). Western blot analysis also showed that wogonin signiﬁ-
antly increased GFAP level after treatment of wogonin (25 M)  for
 days. This increased expression of GFAP was observed with wogo-
in concentrations ranging from 0 to 50 M in C6 and U251 cells
Fig. 3C and D). In addition, gene expression level of GFAP was mea-
ured by real time-PCR and it was found that the mRNA expression
f GFAP increased in the wogonin treatment group as compared tofor 72 h. (E and F) The effect of wogonin (0–50 M)  on the colony formation ability
 with the controls are given as *P < 0.05, **P < 0.01.
the control (Fig. 3E). All these results suggest that wogonin induces
the differentiation of glioma cells into mature glial cells.
3.4. Wogonin exerts its differentiation activity via the inhibition
of GSK-3ˇ/ˇ-catenin pathway in glioma cells
Since the ﬂavonoid wogonin has been shown to induce decrease
in phosphorylated Akt in several types of cells including malignant
216 Y. Wang et al. / Toxicology Letters 222 (2013) 212– 223
Fig. 2. Wogonin induces growth arrest at G0/G1 phase of cell cycle in glioma cells. (A and B) The effect of wogonin on cell cycle proﬁle (C6 (A) or U251 (B)) was  examined
by  ﬂow cytometry analysis. Cells were treated with wogonin at indicated concentration (0–50 M) for 24 h. The experiments were repeated three times, and the result of
a  representative experiment was presented. The quantitative data of cell cycle phase are shown in the (C). (D) The recovery effect of glioma cells to re-enter into cell cycle
after  50 M wogonin treatment was removed for 4, 8, 12 and 24 h. (E and F) Western blotting analysis on principal cell-cycle regulatory proteins in C6 and U251 cells. Cells
were  incubated with different concentration wogonin (0–50 M)  for 24 h. The quantitative data of cell-cycle regulatory protein levels are shown in the (G and H).
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Fig. 3. Wogonin promotes the differentiation of glioma cells into mature glial cells. Cells were incubated with 0, 25 and 50 M wogonin for 3 days. (A) Wogonin promotes
morphological transformation of C6 cells that indicated cell differentiation. (B) Immunocytochemistry of GFAP proteins expression. C6 cells were exposed to 25 and 50 M
wogonin at indicated concentration for 3 days. (C) The effect of wogonin compared with ATRA on GFAP protein by western blot analysis. Cells were treated with 25 M
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togonin or 10 M ATRA for 3 days. (D) Concentration-dependent effect of wogoni
E)  The mRNA level of GFAP protein. Cells were incubated with wogonin (0–50 M
epresentative of at least three independent experiments; **P < 0.01 vs control, *P <
lioma (Huang et al., 2011; Lu et al., 2008; Parajuli et al., 2011), and
SK3, a downstream target molecule of Akt, plays an important
ole in astrocytic differentiation of human glioblastoma cells (He
t al., 2011; Korur et al., 2009; Li et al., 2010a,b), we hypothe-
ized that wogonin induced the differentiation in glioma cells
as associated with decreased activity of Akt/GSK3  signaling.
o test this hypothesis, we analyzed both phosphorylated and
on-phosphorylated forms of Akt in C6 and U251 cells treated with
ndicated doses wogonin or 25 M wogonin for various lengths of
ime (Fig. 4A and B). Our data indicated that Akt was  constitutivelyFAP protein. Cells were incubated with 0, 12.5, 25, and 50 M wogonin for 3 days.
24 h. GFAP mRNA levels were measured by realtime-PCR. Data (mean ± SD) were
s control.
phosphorylated in glioma cells, which was signiﬁcantly inhibited
by the wogonin under a dose- and time dependent manner. Wogo-
nin caused a more pronounced decrease in phosphorylation of Akt
in a time-dependent manner. As proto-oncoproteins -catenin
is putative GSK-3 substrates for phosphorylation-dependent
inactivation, we tested whether wogonin mediated Akt inhibition
could lead to inhibition of GSK-3/-catenin signaling activity.
Western blot analysis also conﬁrmed up-regulated expression of
GSK3 and down-regulated expression of -catenin in glioma
cells treated by wogonin as time and concentration increased
218 Y. Wang et al. / Toxicology Letters 222 (2013) 212– 223
Fig. 4. Akt/GSK-3/-catenin pathway is involved in wogonin induced the differentiation of glioma cells. Wogonin decreased the level of phosphorylated Akt, depend on
dose  (A) and duration (B). Dose- and time-dependent inhibition of GSK-3 and -catenin activities by wogonin was  shown in (C) and (D). The ratios of the quantitative data
are  shown in the under panels. Cells were cultured for 24 h with various doses of wogonin, or with 50 M wogonin for indicated time. The Akt, GSK-3 and -catenin protein
expression and their phosphorylated levels were examined by western blot analysis. Results are expressed as the mean ± S.E.M. of three independent experiments. **P < 0.01
vs  control, *P < 0.05 vs control.
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Fig. 4C and D). In addition, the phosphorylation levels of GSK3
nd -catenin presented reverse change tendency corresponding
o their each protein levels.
To further study -catenin pathway regulating the differentia-
ion of glioma cells, 20 mM LiCl and 20 ng/ml DKK-1 were separately
dded into wogonin treated glioma cells for 3 days. LiCl, as a known
ctivator of canonical -catenin signaling, can inhibit GSK3 activ-
ty and consequently induce accumulation of -catenin. Dkk1 can
ind to LRP5/6 co-receptors for Wnt  ligands, and inhibit -catenin
ignaling. We  found that C6 cells became round and lose the synap-
ic sample structure after LiCl treatment, but Dkk1 signiﬁcantly
romoted C6 cells differentiating into mature glial cells (Fig. 5A).
he result shown in Fig. 5B also illustrated that the expression
evel of -catenin was increased by LiCl and decreased by DKK-1.
ctually, wogonin caused signiﬁcant inhibition of -catenin pro-
ein compared to the separate drug groups. Treatment of C6 and
251 cells with LiCl in the presence of wogonin (50 M)  resulted
ig. 5. Inhibition of -catenin signaling promotes the glial differentiation in glioma cells.
espectively. (A) Wogonin, LiCl, and DKK-1 induced morphological changes of C6 cells (a
B)  -Catenin and GFAP protein levels were examined by western blot analysis. (C) The r
s  the mean ± S.E.M. of three independent experiments. **P  < 0.01 vs control, *P < 0.05 vs crs 222 (2013) 212– 223 219
in apparent down-regulation of GFAP compared to treatment with
wogonin alone. The expression of GFAP was  upregulated after Dkk1
treatment, and this activation by Dkk1 was  increase by the com-
bined with wogonin treatment. These results suggest that blocking
the -catenin signaling treated by Dkk1 promotes the differen-
tiation of glioma cells, while activating this pathway stimulated
by LiCl inhibits glioma cells differentiating into mature glial cells.
We thus concluded that wogonin suppressed the GSK3/-catenin
signaling through attenuating the phosphorylation of Akt, and fur-
ther exerted differentiation-inducing and anti-proliferative effect
in glioma cancer cells.
3.5. Wogonin promotes differentiation of C6 glioma cells in vivoGlioma C6 cells were pretreated with wogonin for 72 h before
intracranial implantation to determine whether wogonin facilitates
the differentiation of C6 cells in vivo as well as in cultured cells, and
 Cells were incubated with 50 M wogonin, 20 mM LiCL or 20 ng/ml Dkk1 for 72 h,
, control; b, LiCl; c, DKK-1; d, wogonin; e, wogonin and LiCl; f, wogonin and Dkk1).
atios of the quantitative data are shown in the under panels. Results are expressed
ontrol.
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educes the capacity of C6 cells to propagate xenografts. Equal num-
ers of viable control or wogonin pretreated cells were implanted
o brain. After 20 days, animals were sacriﬁced and brain sec-
ions were analyzed for tumor formation. All animals injected with
ontrol cells developed tumors. Tumors propagated from wogonin-
retreated cells were also signiﬁcantly smaller than controls
75.9 ± 3.24 vs 117.1 ± 7.86 mm3, P < 0.05) and similar with ATRA
ig. 6. Wogonin induces the glial differentiation of C6 cells in vivo. C6 cells (total 1 × 106
ith  DiI-C18-(3) (DiI, red), and then transplanted into the adult rat brain. (A) H&E stain
agniﬁcation of tumor staining. (B) Brain slices were immunostained with GFAP protein
CNA  staining of wogonin and ATRA-treated xenografts. (D) Tumors from wogonin and
CNA  positive cells in xenografts.rs 222 (2013) 212– 223
group (75.9 ± 3.24 vs 61.3 ± 8.86 mm3, no signiﬁcant difference)
(Fig. 6D). PCNA staining showed that there are about 21.4 ± 2.35%
PCNA+ cells in wogonin-treated tumors vs 41.7 ± 6.73% PCNA+ cell
in control xenografts, but more than 17.2 ± 2.46% PCNA+ cell in
ATRA group, indicating that treatment of wogonin signiﬁcantly
reduced the proliferation of glioma cancer cells, similar to ATRA
(Fig. 6E). To examine the expression of mature glial marker in the
cells) were pre-incubated with 25 M wogonin or 10 M ATRA for 7 days, labeled
ed brain sections from animals after 20 days. The under panels showed a higher
s and images were photographed under a confocal laser scanning microscope. (C)
 ATRA-treated were also signiﬁcantly smaller than controls. (E) The percentage of
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Fig. 7. Intravenous administration of wogonin inhibits tumor growth and enhances survival of glioma-bearing rats. (A) Eighteen days after tumor transplantation, gadolinium
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snhanced MRI  was  performed. (B) Tumor volume was estimated following gadolinium
njection on body weight. (D) Brain slices were immunostained with GFAP protein
urvival curve of glioma-bearing rats after various wogonin and DDP treatment.
ransplanted glioma cells, we stained the brain sections with anti-
FAP antibody. Fig. 6B showed increased staining for GFAP in brain
lices treated by wogonin. These observations indicate that wogo-
in accelerates the differentiation of C6 cells into mature glial cells
n vivo.
.6. Wogonin inhibits tumor growth and enhances survival of
lioma-bearing rats
The anti-glioma effect of wogonin was further assessed with
rthotopically transplanted glioma model in vivo. Cisplatin (DDP),
s the positive control, is one of the most commonly used and
he most effective chemotherapeutic agents for glioma patients.
RI  analysis on day 18 after tumor transplantation showed that
he tumor volume in the untreated rat was approximately 2.5
imes greater than in the rat receiving high concentration wogo-
in administration (Fig. 7A) Quantiﬁcation analysis of the tumor
izes revealed that the tumor sizes of medium- and high-wogonin
reated groups were decreased compared to control group as
hown in Fig. 7B. Symptoms of weight loss were not observed dur-
ng all experiment groups except DDP group (Fig. 7C). To evaluate
hether wogonin caused differentiation of C6 glioma cells, GFAP
taining was used to examine tumor tissue. Increased expression ofnced MRI  on day 8, 13 and 18. (C) The effect of wogonin administered by intravenous
 images were photographed under a confocal laser scanning microscope. (E) The
GFAP protein was present in the C6 tumor following medium and
high dose wogonin treatment (Fig. 7D). Survival analysis revealed
that the median survival of untreated animals was only 13.5 days,
while the median survival of medium- and high dose wogonin
treated animals were 21 days (Fig. 7E). This indicated a substantial
delay in growth of glioma by wogonin.
4. Discussion
S. baicalensis,  a popular and multi-purpose herb used in tradi-
tional Chinese medicine, has been conﬁrmed to have anticancer
activities (Parajuli et al., 2009). A recent study provided the in vivo
evidence and mechanistic support for anti-glioma activity of Scutel-
laria extract (Parajuli et al., 2011). Its biological activities have been
attributed mainly to the constituent ﬂavonoids. Wogonin, as one
of the prominent composition from Scutellaria extract (Li-Weber,
2009), was found to exert cytotoxic effects, inhibit cell proliferation,
and potently induce cell apoptosis and G1 phase arrest in sev-
eral cancer cells, such as human cervical cancer HeLa cells, human
hepatoma cells SMMC-7721, promyelocytic leukemia U-937, hepa-
tocellular carcinoma cells SK-HEP-1, human lung cancer cell lines
A549, SK-LU-1 and SK-MES-1 (Chen et al., 2002; Gao et al., 2011;
Yang et al., 2009). Recently, several in vitro studies reported that
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ogonin increased cellular ROS and ER stress, blocked cell cycle
rogression at the G1 phase, and induced human glioma cell apo-
tosis by inducing p53 expression and upregulating p21 expression
Lee et al., 2012; Tsai et al., 2012). Previous studies have focused on
he effect of wogonin on induction of the apoptosis of tumor cells,
ut the apoptosis rate was  much less than the rate of growth inhi-
ition. Therefore, other mechanisms may  involve in the inhibition
f glioma cells proliferation.
The rate of cell proliferation within any type of cells depends on
hree factors: the length of time to complete a cell division cycle,
he fraction of cells within the population undergoing cell division,
nd the rate of cell loss from the population due to terminal differ-
ntiation or cell death. In mammalian cells, the length of G1 phase is
ighly variable and determines most of the difference in cell divi-
ion time between different cell types or between cells growing
nder different conditions. Increasing evidence demonstrates that
ogonin-induced cancer cell death through induction of cell apo-
tosis and ER stress (Lee et al., 2012; Tsai et al., 2012; Xu et al., 2012;
ang et al., 2013). Our ﬁndings are very consistent with previously
eported data, and showed that 50 M wogonin induces about 50%
nhibition of cell proliferation and 1.5-fold increase of sub-G1 arrest
n U251 glioma cells.
Escape from the tissue/lineage-speciﬁc differentiation is one of
he fundamental aspects of tumorigenesis. The aberrantly differ-
ntiated cells display abnormal growth characteristics and more
nvasive and metastatic phenotype. Upon appropriate stimulus,
alignant cancer cells enter into reprogramming process, loss pro-
iferative capacity and induce differentiation. After tumor cells have
een induced to undergo terminal differentiation, their ability to
row as a tumor often is stably suppressed. Cell proliferation and
ifferentiation are speciﬁcally controlled in the G1 phase and the
1/S phase transition in the cell cycle (Nurse, 2000). The present
tudy showed that wogonin triggered glioma cells morphologic
ransformation indicative of the cell differentiation into a more
ature state, accompanied by up-regulated expression of GFAP, a
ype III intermediate ﬁlament protein considered to be the most
eliable marker of glial differentiation. This differentiation trig-
ered by wogonin was also accompanied by cellular proliferation
nhibition and accumulation of cells in the G0/G1phase of the
ell cycle at multiple points within the machinery governing the
1/S transition. The expressions of G1/S control proteins cyclin D1,
DK2, and CDK4 were down-regulated and associated with pro-
ound increased p27. Therefore, wogonin induced sub-G1 arrest,
ell apoptosis and cell differentiation have come together to lead
o cell proliferation inhibition in glioma cells.
In mammalian cells the G1 to S phase transition is regulated by
he G1 cyclins, such as cyclin D1 and cyclin E, which bind to and
ctivate the CDK4 and CDK2 protein kinases, respectively. Of these
wo G1 cyclins, cyclin E shows the most dramatic cell cycle varia-
ion in mRNA, protein and associated CDK protein kinase activity,
eaking in late G1 phase just prior to S phase. The CDK inhibitors
21 and p27 play important roles in mediating growth arrest and
locking the G1 to S transition of the cell cycle (Massague, 2004).
he increase in p21 and p27 could, by inhibiting cyclin D1/CDK4 and
ycle E/CDK2 kinase activity, explain, at least in part, the increase of
ells in the G1/G0 phase by wogonin treatment in our experiments.
Recent studies have shown that cyclin D1 function not only
s positive cell cycle regulators but also function as co-factors
or several transcription factors (Wang et al., 2003). Increasing
umber of reports have demonstrated that inhibition of cyclin D1
as able to induce differentiation of tumor cells such as glioma
ells, melanoma cells and neuroblastoma cells (Georgopoulou et al.,
006; He et al., 2011; Wang et al., 2003). The bioavailability
f cyclin D1 is regulated at the genetic level by transcriptional
odulation and also through ubiquitin-dependent proteolysis fol-
owing phosphatidylinositol 3-kinase (PI3K)/Akt/glucose synthasers 222 (2013) 212– 223
kinase-3 (GSK-3) pathway activation, especially the GSK-3 activ-
ity (Wang et al., 2003). A series of experiments proved that GSK-3
plays an important role in astrocytic differentiation of human
glioblastoma cells (Korur et al., 2009; Li et al., 2010a,b). GSK-3
is a multifunctional serine/threonine kinase, negatively regulated
by of PI3K-mediated activation of Akt. In the regulation of gene
expression, GSK-3 is transformed to its inactive form by phos-
phorylating speciﬁc amino terminal residues such as Ser 33, Ser 37,
and Thr 41, which causes the attenuated degradation of cytoplas-
mic  -catenin, then activates Wnt/-catenin signaling and ﬁnally
enhances the cyclin D1 promoter activity. In proteasome-mediated
cyclin D1 degradation, GSK-3 phosphorylation at Ser 9 facilitates
the sustainment of cyclin D1 stability, which means that dephos-
phorylation would promote cyclin D1 degradation (Cohen and
Frame, 2001; Takahashi-Yanaga and Sasaguri, 2008). Our results
showed that wogonin attenuated the GSK-3 phosphorylation
levels at Ser 9 and down-regulated -catenin expression. This
activation of GSK-3 is precisely due to inhibition of Akt activity
caused by wogonin. Interestingly, inhibition of GSK-3 activity by
LiCl decreased the downregulation of -catenin protein induced
by wogonin and suppressed differentiation of glioma cells into
astrocytes. Conversely, decreased expression of -catenin by Wnt
signaling inhibitor DKK1 caused the remarkable reduction of the
cellular -catenin protein, increased the protein GFAP expression
and promoted the differentiation in C6 and U251 cells. These results
sufﬁciently conﬁrmed that wogonin induce the G1/G0 arrest in
cell cycle and the differentiation into mature astrocytes through
disrupted the stability of cyclin D1 by inhibiting GSK-3.
As in vitro experiment results identiﬁed the effect of wogonin
on cell growth inhibition and promoting differentiation, we  estab-
lished rat intracerebral tumor model to observe whether wogonin
leads to consistent results in the in vivo setting. Wogonin pretreated
C6 cells were injected into rat brain and both the tumor size and
tumor propagation rate are signiﬁcantly decreased. The results of
GFAP marker expression and PCNA staining also conﬁrmed that
wogonin caused the inhibition of proliferation and differentiation
in C6 cells. Subsequently, we further investigated the anti-glioma
effect of wogonin in orthotopically transplanted tumor model. Base
on our previous observation, the LD50 of wogonin administered by
the intravenous injection was  286.15 mg/kg and the 95% conﬁdence
limit was  278.27–295.26 mg/kg (Qi et al., 2009). Thus, the range
of 30–120 mg/kg was chosen as appropriate concentration range
of wogonin in in vivo experiment. Our results showed that intra-
venous administration of wogonin markedly delayed the glioma
tumor growth and enhanced survival rate in glioma-bearing rats.
In conclusion, we  conﬁrmed that wogonin might be a
differentiation-inducer in glioma cells intensiﬁed therapeutic
interest in the treatment of glioma. This effect may be caused by G1
arrest in the cell cycle ascribed to the restrain of cyclin D1, CDK2
and CDK4 activities by augmented expression of p27 protein. Of  the
various possibilities for wogonin-induced differentiation, inhibited
Akt/GSK-3/-catenin pathway represents a plausible candidate.
Signiﬁcantly, wogonin, an effective ﬂavonoids monomer, may  be
a novel inducer with substantial differentiation potential in the
therapy of malignant glioma.
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